ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Autism Spectrum DisorderML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
12 to 45
Participation Criteria
Inclusion Criteria:
* Age 12 to 45 at screening
* Has a designated care/study partner who can reliably report on symptoms
* Has a diagnosis of Autism Spectrum Disorder (ASD)
* Has a body mass index (BMI) 18 through 34 kg/m², inclusive
* Full scale IQ (or equivalent) ≥55 score, with adequate verbal fluency, as determined by the Principal Investigator.
* Psychoactive medications and adjunctive therapies are stable for 4 weeks prior to screening
* Must be able to swallow study medication
Exclusion Criteria:
* Has Rett syndrome or Child Disintegrative Disorder
* Has participated in any other study and received any other investigational medication (other than COVID-19 vaccination) or device within 60 days prior to screening
* History of epilepsy without current adequate control, or any seizure in the 6 months preceding screening
* History of suicidal ideation or behavior in the past 12 months, or a positive response to C-SSRS questions 4 and/or 5
* Systolic blood pressure ≥140 mmHg (if adult) or \>135 mmHg (if adolescent), or diastolic blood pressure ≥90 (if adult) or \>85 mmHg (if adolescent), or a clinical history of uncontrolled or severe hypertension
* If female, is pregnant or lactating
Study Location
Holland Bloorview Kids Rehabilitation Hospital
Holland Bloorview Kids Rehabilitation HospitalToronto, Ontario
Canada
Contact Study Team
Danielle Baribeau, MD, PhD
416-425-6220OCT Research ULC (dba Okanagan Clinical Trials)
OCT Research ULC (dba Okanagan Clinical Trials)Kelowna, British Columbia
Canada
Contact Study Team
Euguene Okorie, MD
250-862-8141Lawson Health Research Institute/ London Health Sciences Centre
Lawson Health Research Institute/ London Health Sciences CentreLondon, Ontario
Canada
Contact Study Team
Rob Nicolson, MD, FRCP (C)
519-685-8427- Study Sponsored By
- MapLight Therapeutics
- Participants Required
- More Information
- Study ID:
NCT05081245